What is Cognition Therapeutics, Inc. (CGTX) stock price today?

Cognition Therapeutics, Inc. (CGTX) is currently trading at $0.89, down 1.05% today.

What is CGTX P/E ratio?

Cognition Therapeutics, Inc.'s P/E ratio is -4.82. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CGTX return on equity (ROE)?

Cognition Therapeutics, Inc.'s return on equity (ROE) is -50.17%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Cognition Therapeutics, Inc.'s market cap?

Cognition Therapeutics, Inc. has a market capitalization of $79.28M.

NASDAQ · Biotechnology

Cognition Therapeutics, Inc. (CGTX) Stock

$0.89 -1.05% NASDAQ: CGTX Healthcare

Valuation

Metric	Value
Price	$0.89
Market Cap	$79.28M
P/E Ratio	-4.82
P/B Ratio	2.54
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$2.05
52-Week Low	$0.55
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-50.17%
ROA	-43.13%
ROCE	-109.43%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.02
Current Ratio	3.43

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-29.0M	$-44.0M	$-51.0M	$-54.0M	$-48.0M
Net Profit	$-12.0M	$1.0M	$-26.0M	$-34.0M	$-23.0M
EPS	$-0.73	$-0.74	$-0.86	$-0.85	$-0.32
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$59.0M	$50.0M	$35.0M	$30.0M	$48.0M
Total Liabilities	$8.0M	$10.0M	$11.0M	$11.0M	$14.0M
Cash	$55.0M	$42.0M	$30.0M	$25.0M	$37.0M
Borrowings	$0	$1.0M	$1.0M	$1.0M	$1.0M

Latest News

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit GlobeNewswire · Jul 13, 2026 Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33% Stocktwits · Jun 24, 2026 Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX) InvestorsHub · Jun 24, 2026 Cognition Therapeutics Agrees With FDA on Phase 3 Trial Framework for Psychosis Treatment MT Newswires · Jun 24, 2026 Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes GlobeNewswire · Jun 24, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-4.0M	$-19.0M	$-16.0M	$-28.0M	$-25.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$9.0M	$2.0M	$0	$0	$0
Net Cash Flow	$50.0M	$-13.0M	$-12.0M	$-5.0M	$12.0M
Free Cash Flow	$-4.0M	$-19.0M	$-16.0M	$-28.0M	$-25.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.03
EV / EBITDA	-2.97
FCF Yield	-21.38%
Quick Ratio	7.03
Interest Coverage	-2815.46
Return 1Y	65.49%
Return 3Y	-45.66%
Return 5Y	—

Ownership

Insiders Held1.37%

Institutions Held25.02%

Institutions Float Held25.36%

Institutional Holder	Shares	Report Date
Bios Capital Management, LP	6,000,000	2026-03-31
Davenport & Co LLC	4,259,511	2026-06-30
Vanguard Capital Management LLC	3,001,787	2026-03-31
Renaissance Technologies, LLC	1,117,136	2026-03-31
Chescapmanager LLC	997,029	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AGENAgenus Inc.	$7.62	+0.99%	3.66	$317.11M	0.00%
ATOSAtossa Therapeutics, Inc.	$2.44	+0.83%	-0.54	$24.34M	0.00%
GLSIGreenwich LifeSciences, Inc.	$16.01	+5.73%	-11.03	$234.96M	0.00%
IRDOpus Genetics, Inc.	$4.65	+4.26%	-3.47	$383.93M	0.00%
MCRBSeres Therapeutics, Inc.	$2.74	+3.99%	-1.21	$26.49M	0.00%

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. is led by CEO Lisa Ricciardi, employs 25 people, headquartered in US, publicly traded since 2021.

Cognition Therapeutics, Inc. (CGTX) stock trades at $0.89 with a market capitalization of $79.28M. The stock is valued at a price-to-earnings (P/E) ratio of -4.82, price-to-book of 2.54, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.55 and $2.05, and currently trades 56.6% below its 52-week high.

On profitability, Cognition Therapeutics, Inc. generates a return on equity (ROE) of -50.17%, return on capital employed of -109.43%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides